AUTHOR INDEX

(P = Proceedings)

AARON, L. *see* DE ALWIS, D.P.
ADEDOYIN, A., FRYE, R.F., MAURO, K. & BRANCH, R.A. Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail, 215
AIKEN, T.C. *see* DEVEREUX, G.
AJJAN, R.A. *see* HUSSAIN, F.N.
ALINCIC, S. *see* SCHWAGMEIER, R.
ALLANSON, J. *see* SEABER, E.J.
AL-RASHED, S.A., WRIGHT, D.J. & CHRYSTYN, H. The opinions of general practitioners on discharge information, 300P
ALVÁN, G. *see* WAKELKAMP, M.
AMREIN, R. *see* SALEMING, W.
ANDERSON, B.J., HOLFORD, N.H.G., WOOLLARD, G.A. & CHAN, P.L.S. Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children, 237
ANDERSON, C. *see* CROSS, S.E.
ANDERSON, R.A. *see* ELLIS, G.R.
ANGUS, P. *see* NAWARATNE, S.
ANNANE, D., BELLISSANT, E., SEBILLE, V., LESIEUR, O., MATHIEU, B., RAPHAEL, J.C. & GAJDOS, P. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve, 589
ARMSTRNG, G. *see* LIPSCOMB, G.R.
ARNOLD, O. *see* BAILEY, D.G.
ARONSON, J.K. Medical Pharmacology at a glance (Book review), 91
ASHTON, H. *see* BIRCH, D.
ASSASSI, K. *see* KIRCHNER, G.I.
ATZPODIEN, J. *see* KIRCHNER, G.I.
AUSTIN, C.A. *see* OATES, A.
AYKROYD, R.G. *see* WRIGHT, D.J.

BABER, N. *see* TOWARD, T.
BABIKER, A.G. *see* CHURCHILL, D.R.
BACK, D.J. *see* EAGLING, V.A.
BACK, D.J. *see* HALIFAX, K.L.
BACK, D.J. *see* KEWN, S.
BACK, D.J. *see* PHIBOONBANAKIT, D.
BACK, D.J. *see* PROFIT, L.
BAILEY, D.G., MALCOLM, J., ARNOLD, O. & SPENCE, J.D. Grapefruit juice–drug interactions, 101
BAK, D.J. *see* CHURCHILL, D.R.
BAKER, H. *see* BARDSLEY, H.
BALLARÍN, E. *see* LAPORTE, J.-R.
BARDSLEY, H., GRISTWOOD, R., BAKER, H., WATSON, N. & NIMMO, W. A comparison of the cardiovascular effects of levobupivacaine and *rac*-bupivacaine following intravenous administration to healthy volunteers, 245
BARDY, A.H. Bias in reporting clinical trials, 147
BARNES, S. *see* RAMSAY, L.
BARRINGTON, P. *see* PALMER, J.L.
BARRY, M. *see* NAISBITT, D.J.
BARRY, M.G. *see* HALIFAX, K.L.
BARRY, M.G. *see* KEWN, S.
BARRY, M.G. *see* PHIBOONBANAKIT, D.
BATTY, A.B. *see* MORRIS, R.G.
BATTY, K.T. *see* MAGGS, J.L.
BEIJNEN, J.H. *see* HERBEN, V.M.M.
BEIJNEN, J.H. *see* HUITEMA, A.D.R.
BEIJNEN, J.H. *see* MALINGRE, M.M.
BEIJNEN, J.H. *see* MEERUM TER WOGT, J.M.
BEIL, W. *see* KIRCHNER, G.I.
BELL, A. *see* KHAKOO, S.
BELLISSANT, E. & GIUDICELLI, J.-F. Pharmacokinetic–pharmacodynamic model relating zabiciprilat plasma concentrations to brachial and femoral haemodynamic effects in normotensive volunteers, 383
BELLISSANT, E. *see* ANNANE, D.
BESSARD, G. *see* STANKE, F.
BEUKEMA, J. *see* PEETERS, P.A.M.
BEUN, A.M. *see* DE HAAN, G.J.
BEUSENBERG, F.B. *see* HERBEN, V.M.M.
BHAT, G.J. *see* PEETERS, P.A.M.
BIEMBA, G. *see* PEETERS, P.A.M.
BILLAUD, E.M., GUILLEMAIN, R., TASCO, F. & CHEVALIER, P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients, 271
BIRCH, D., ASHTON, H., KELLY, P. & KAMALI, F. Alcohol and illicit drug use in junior hospital doctors in the north east of England, 278P
BIRCH, D., WHITE, M., KELLY, P. & KAMALI, F. Alcohol, illicit drug use and lifestyle variables in a cohort of first year medical students at Newcastle University, 301P
BIRD, D. *see* DURSUN, S.M.
BIRKETT, D.J. *see* MCMANUS, P.
BISHOP, L.P.D., MAGGS, J.L. O'NEILL, P.M. & PARK, B.K. The metabolism of arteflene (Ro 42–1611), an endoperoxide antimalarial, in rats, 293P
BISWAS, P.N. *see* MARTIN, R.M.
BLACK, A.B. *see* MORRIS, R.G.
BLASCHKE, T.F. & JAILLON, P. Discussion session. The solution, 356
BOAKYE, E. *see* FREUDENTHALER, S.
BODE-BÖGER, S.M., BÖGER, R.H., GALLAND, A., TSIKAS, D. & FRÖLICH, J.C. L-arginine-induced vasodilation in healthy humans: pharmacokinetic–pharmacodynamic relationship, 489
BÖGER, R.H. *see* BODE-BÖGER, S.M.
BOIKE, S.C. *see* TENERO, D.M.
BOOCOCK, D.J., MAGGS, J.L., WHITE, I.N.H. & PARK, B.K. Identification and quantification of -hydroxytamoxifen, a genotoxic metabolite of tamoxifen, 296P
BOURKE, S.J. *see* DEVEREUX, G.
BOUWELS, L.H.R. *see* VAN KRAAIJ, D.J.W.
BOYCE, M. *see* WARRINGTON, S.
BOYD, A. *see* JOUBERT, P.
BRACCHI, R. HUTCHINGS, A.D., WOODS, F.J., HOUGHTON, J., SMAIL, S.A. & ROUTLEDGE, P.A. Spontaneous reporting of suspected adverse drug reactions by general practitioners in a UK health region, 279P
BRADY, P.A., CHARLETT, A., DOBBS, R.J., PETERSON, D.W., WILKS, M., WELLER, C. & DOBBS, S.M. Increased prevalence of *Helicobacter pylori* seropositivity in sufferers from idiopathic parkinsonism and their siblings, 302P
BRANCH, R.A. Implications of liver disease for regulatory requirements for drug development, 351
BRANCH, R.A. *see* ADEOYIN, A.
BRÉANT, D. *see* STANKE, F.
BRECKENRIDGE, A. *see* REIDENBERG, M.M.
BRETT, S.E., RITTER, J.M. & CHOWIENCZYK, P.J. Association between metabolic risk factors and exercise blood pressure in health men, 288P
BREYER-PFAFF, U. *see* SCHABER, G.
BRICCA, G. *see* STANKE, F.
BRIEN, J.E. *see* NAWARATNE, S.
BRINKMAN, K. *see* BURGER, D.M.
BRINKMAN, K. *see* HUGEN, P.W.H.
BROOKS, B. *see* PROFIT, L.
BROUWERS, J.R.B.J. *see* VAN DIJK, K.N.
BROWN, A.S. *see* FONTANA, R.J.
BROWN, O. *see* RIDGE, S.A.
BROWN, R.R. *see* FONTANA, R.J.
BRUNNER, M., SCHMIEDBERGER, A., SCHMID, R., JÄGER, D., PIEGLER, E., EICHLER, H.G. & MÜLLER, M. Direct assessment of peripheral pharmacokinetics in humans: comparison between cantharides blister fluid sampling, *in vivo* microdialysis and saliva sampling, 425
BRYSSINE, B. *see* PALMER, J.L.
BUER, J. *see* KIRCHNER, G.I.
BURGER, D.M. *see* HUGEN, P.W.H.
BURGER, D.M., HOETELMANS, R.M.W., HUGEN, P.W.H., MULDER, J.W., MEENHORST, P.L., KOOPMANS, P.P., BRINKMAN, K. & HEKSTER, Y.A. Plasma levels of indinavir (IDV) and virological treatment failure in HIV-infected patients, 620P
BURGGRAAF, J., VAN HAARST, A.D., FOCKENS, P., SCHOEMAKER, H.C., KRAUWINKEL, W.J.J. &

© 1998 Blackwell Science Ltd

COHEN, A.F. The gastrointestinal passage and release of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers, 207
BUSS, D.C. *see* SHETTY, H.G.M.
BUTLER, A.R. *see* KHAN, S.Q.
BUTLER, R., MORRIS, A.D., LEONE, A. & STRUTHERS, A.D. Can endothelial function be assessed *in vivo* by measuring acetylcholine induced changes in nitrate in the forearm in man?, 517
BUTTER, J.J. *see* SCHIPPER, H.G.
BUTTERS, C.J. *see* WILD, M.J.
BYE, C. *see* TOWARD, T.

CALDWELL, J. *see* SOMCHIT, N.
CAMPBELL, N.R.C. *see* SCHAEFER, J.P.
CAMPBELL, T.J. & WILLIAMS, K.M. Therapeutic drug monitoring: antiarrhythmic drugs, 307
CAVANAUGH, J.H. *see* OUELLET, D.
CHAN, P.L.S. *see* ANDERSON, B.J.
CHANNER, K.S. *see* OATES, A.
CHANNER, K.S. *see* STEEDS, R.P.
CHARLETT, A. *see* BRADY, P.A.
CHEVALIER, P. *see* BILLAUD, E.M.
CHEVANON, O. *see* STANKE, F.
CHEVRET, S. *see* FABRE, E.
CHOUDHURY, R.P. & MACDERMOT, J. Heart failure in thyrotoxicosis, an approach to management, 421
CHOWIENCZYK, P.J. *see* BRETT, S.E.
CHOWIENCZYK, P.J. *see* FONTANA, L.
CHOWIENCZYK, P.J. *see* KNEALE, B.J.
CHRYSTYN, H. *see* HAWKSWORTH, G.M.
CHRYSTYN, H. *see* AL-RASHED, S.A.
CHRYSTYN, H. *see* WRIGHT, D.J.
CHURCHILL, D.R., PYM, A.S., BABIKER, A.G., BACK, D.J. & WEBER, J.N. Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection, 518
CLARK, D.J. *see* LIPWORTH, B.J.
CLARKE, A. *see* WARRINGTON, S.
CLEOPHAS, T.J. *see* TEN HAVE, S.M.
CLEOPHAS, T.J. *see* VAN DER MEULEN, J.
COCKCROFT, J.R. *see* WILKINSON, I.B.
COHEN, A.F. *see* BURGGRAAF, J.
COLLINS, P. *see* ROUTLEDGE, R.A.
CORRADI, L. *see* FOGARI, R.
COSOLO, W. *see* NAWARATNE, S.
CROSS, S.E., ANDERSON, C. & ROBERTS, M.S. Topical penetration of commercial salicylate esters and salt using isolated human skin and clinical microdialysis studies, 29

D'ATHIS, P. *see* FABRE, E.
DA SILVA, C.M.F., DAVID, F.L., MUSCARÁ, M.N., SOUSA, S.S., FERRAZ, J.G.P., DE NUCCI, G., POLIMENO, N.C. & PEDRAZZOLI, J. Plasma hydroxy metronidazole/metronidazole ratio in anti-HCV carriers with and without apparent liver disease, 176
DANIEL, M.J. *see* JOHNSON, M.A.
DARGIE, H.J. End points and surrogate markers in heart failure, 361
DASH, C. *see* KHAKOO, S.
DAVENPORT, A.P. *see* LONGMORE, J.
DAVID, F.L. *see* DA SILVA, C.M.F.
DE ALWIS, D.P., AARONS, L. & PALMER, J.L. Population pharmacokinetics of ondansetron: a covariate analysis, 117
DE BROE, M.E. *see* JOHNSON, M.A.
DE GIER, J.J. *see* VAN KRAAJI, D.J.W.
DE HAAN, G.J., BEUN, A.M., ENGELSMAN, M., RADEMAKER, M.V., DEBETS, R.M.C. &
DE HOON, J.N.J.M., PICKKERS, P., SMITS, P. & VAN BORTEL, L.M.A.B. Is calcitonin gene-related peptide induced vasodilation endothelium-dependent in man?, 621P
DE JONG-VAN DEN BERG, L.T.W. *see* VAN DIJK, K.N.
DE NUCCI, G. *see* DA SILVA, C.M.F.
DE PLANQUE, B.A. *see* TEN HAVE, S.M. DE STOPPELAAR, F.M., STOLK, L.M.L., STAPPERS, J.L.M. & GORGELS, A.P.M. Rectal administration of metoprolol: pharmacokinetic and pharmacodynamic aspects, 622P
DE VRIES, C.S. *see* VAN DIJK, K.N.
DEBETS, R.M.C. *see* DE HAAN, G.J.
DEBILLON, T. *see* PAWLOTSKY, F.
DEKKER, S., WOUTERSE, A.C., STEEGERS, E.A.P., RUSSEL, F.G.M. & SMITS, P. The role of endothelium derived nitric oxide in the regulation of vascular tone in pre-eclamptic and normotensive human placentae, 622P
DELEU, D. Levodopa monitoring by retrodialysis, 88
DESBOEUF, K., LAPEYRE-MESTRE, M. & MONTASTRUC, J.-L. Risk of gastrointestinal haemorrhage with calcium antagonists, 88
DEVEREUX, G., FISHWICK, K., AIKEN, T.C., BOURKE, S.J. & HENDRICK, D.J. Adverse effects of a single dose of D-sotalol in patients with mild stable asthma, 79
DEVILLIER, P. *see* STANKE, F.
DEVRIES, T.M. *see* FONTANA, R.J.
DIASIO, R.B. Sorivudine and 5-fluorouracil; a clinically significant drug–drug interaction due to inhibition of dihydropyrimidine dehydrogenase, 1
DIEMUNSCH, P. *see* PALMER, J.L.
DIETZ, K. *see* SCHABER, G.
DIJKEMA, A.M. *see* VAN DIJK, K.N.
DING, R.W. *see* PORT, R.E.
DINGEMANSE, J. *see* SALEMING, W. disposition and toxicity of sulphones and sulphonamides, 305P
DOBBS, R.J. *see* BRADY, P.A.
DOBBS, S.M. *see* BRADY, P.A.
DONNELLY, R. *see* UEDA, S.
DOYLE, K. & TINER, R. Training and development conferences for members of research ethics committees assessing clinical pharmacology studies, 347
DRAGO, F., LA MANNA, C., MARINO, V., MARINO, A., EMMI, I. & REIBALDI, A. Norfloxacin exhibits negligible serum concentrations after repeated conjunctival instillation in children, 272
DUCHIN, K. *see* MALINGRE, M.M.
DUCHIN, K. *see* MEERUM TER WOGT, J.M.
DURSUN, S.M., BIRD, D. & FLINN, J. Olanzapine in treatment-resistant schizophrenic patients: preliminary results from an open prospective study, 301P
DUSHEIKO, G.M. *see* KHAKOO, S.

EADIE, M.J. Therapeutic drug monitoring — antiepileptic drugs, 185
EAGLING, V.A., HALIFAX, K.L. & BACK, D.J. Inhibition of CYP2D6-mediated bufuralol hydroxylation by HIV-protease inhibitors, 295P
EASON, C.J. *see* OUELLET, D.
EDELBROEK, P.M. & VERMEIJ, T.A.C. Pharmacokinetics of vigabatrin enantiomers by new h.p.l.c. method using a simple precolumn derivatization with OPA/N-acetyl-cysteine, 627P
EDWARDS, G. *see* MAGGS, J.L.
EGBERTS, A.C.G. *see* VAN DEN BEMT, P.M.L.A. EGBERTS, A.C.G. *see* VAN ROON, E.N. ELIAS, E. Classification of severity and aetiology of liver impairment, 354
EICHLER, H.G. *see* BRUNNER, M. ejection fraction, 624 P
ELIASSON E. *see* RAMSAY, L.
ELLIOTT, H.L. *see* ROSARIO, M.C.
ELLIOTT, H.L. *see* UEDA, S.
ELLIS, G.R., ANDERSON, R.A., JACKSON, S.K., LANG, D., FRENNEAUX, M.P. & LEWIS, M.J. The acute effects of vitamin C on endothelial function and oxidative stress in chronic heart failure, 279P
ELTHERINGTON, L.G. *see* MATHER, L.E.
EMMI, I. *see* DRAGO, F.
ENGELSMAN, M. *see* DE HAAN, G.J.
GILL, H.J., TINGLE, M.D., PIRMOHAMED, M. & PARK, B.K. Relationship between the
ENSLEN, M. *see* PATAT, A.
EZZET, F., MULL, R. & KARBWANG, J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients, 553

FABINY, R. *see* NAWARATNE, S.
FABRE, E., CHEVRET, S., PIECHAUD, J-F., REY, E., VAUZELLE-KERVROEDAN, F., D'ATHIS, P., OLIVE, G. & PONS, G. An approach for dose finding of drugs in infants:

sedation by midazolam studied using the continual reassessment method, 395
FARR, S.J. *see* MATHER, L.E.
FEENSTRA, J., IN'T VELD, B.A., VAN DER LINDEN, P.D., GROBBEE, D.E. & STRICKER, B.H.CH. Risk factors for mortality in users of ibopamine, 71
FERNANDEZ-SALGUERO, P.M. *see* RIDGE, S.A.
FERRAZ, J.G.P. *see* DA SILVA, C.M.F.
FIES, T. *see* PORT, R.E.
FISHWICK, K. *see* DEVEREUX, G.
FLANNERY, B. *see* KHAKOO, S.
FLINN, J. *see* DURSUN, S.M.
FLOREANI, M. *see* ORLANDO, R.
FOCKENS, P. *see* BURGGRAAF, J.
FOGARI, R., ZOPPI, A., CORRADI, L., LAZZARI, P., MUGELLINI, A. & LUSARDI, P. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients, 467
FONTANA, L., McNEILL, K.L., RITTER, J.M. & CHOWIENCZYK, P.J. Inhibitory effects of low-density lipoprotein on endothelium-dependent relaxation are attenuated by vitamin C and A cell permeable superoxide dismutase mimetic, 288P
FONTANA, R.J., DEVRIES, T.M., WOOLF, T.F., KNAPP, M.J., BROWN, A.S., KAMINSKY, L.S., TANG, B.K., FOSTER, N.L., BROWN, R.R. & WATKINS, P.B. Caffeine based measure of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease, 221
FOSTER, N.L. *see* FONTANA, R.J.
FRANZKE, A. *see* KIRCHNER, G.I.
FREEMANTLE, S.N. *see* MARTIN, R.M.
FRENNEAUX, M.P. *see* ELLIS, G.R.
FREUDENTHALER, S., MEINEKE, I., SCHREEB, K.-H., BOAKYE, E., GUNDERT-REMY, U. & GLEITER, C.H. Influence of urine pH and urinary flow on the renal excretion of memantine, 541
FRÖLICH, J.C. *see* BODE-BÖGER, S.M.
FRYE, R.F. *see* ADEOYIN, A.
FUMOLEAU, P. *see* PALMER, J.L.

GABRIELSSON, J. *see* WAKELKAMP, M.
GAERTNER, H.J. *see* SCHABER, G.
GAJDOS, P. *see* ANNANE, D.
GALLAND, A. *see* BODE-BÖGER, S.M.
GANDON, J.M. *see* PATAT, A.
GANSER, A. *see* KIRCHNER, G.I.
GARDINER, I. *see* RAMSAY, L.
GERTZ, B.J. *see* REID, K.
GIUDICELLI, J-F. *see* BELLISSANT, E.
GLEITER, C.H. *see* FREUDENTHALER, S.
GLUE, P. *see* KHAKOO, S.
GO, I.H. *see* VAN KRAAIJ, D.J.W.
GORGELS, A.P.M. *see* DE STOPPELAAR, F.M.
GRIBNAU, F.W.J. *see* VAN KRAAIJ, D.J.W.
GODFREY, C., SWEENEY, K., MILLER, K., HAMILTON, R. & KREMER, J. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis, 369
GOLDING, J.F. *see* REID, K.
GONG, P.L. *see* LI, G.
GONZALEZ, F.J. *see* RIDGE, S.A.
GRAHAM, E. *see* PALMER, J.L.
GRANNEMAN, G.R. *see* OUELLET, D.
GREENE, D.S. *see* VACHHARAJANI, N.N.
GRELLIER, L. *see* KHAKOO, S.
GREWAL, H.K. *see* TOWARD, T.
GRIBNAU, F.W.J. *see* VAN KRAAIJ, D.J.W.
GRISTWOOD, R. *see* BARDSLEY, H.
GROBBEE, D.E. *see* FEENSTRA, J.
GROENEWEGEN, G. *see* MEERUM TER WOGT, J.M. GUPTA, V. *see* VAN AGTMAEL, M.A. HEKSTER, Y.A. *see* BURGER, D.M.
GROSS, A.S. Best practice in therapeutic drug monitoring, 95
GROSS, A.S. *see* HOSKINS, J.M.
GUILLEMAIN, R. *see* BILLAUD, E.M.
GUNDERT-REMY, U. *see* FREUDENTHALER, S.

HADERSLEV, K.V., SONNE, J., POULSEN, H.E. & LOFT, S. Paracetamol metabolism in patients with ulcerative colitis, 513
HALIFAX, K.L. *see* EAGLING, V.A.
HALIFAX, K.L., LINDUP, W.E., BARRY, M.G., WILTSHIRE, H.R. & BACK, D.J. Binding of the HIV protease inhibitor saquinavir to human plasma proteins, 291P
HAMILTON, R. *see* GODFREY, C.
HARRIS, A.L. *see* MORRIS, R.G.
HARRY, F. *see* SHETTY, H.G.M.
HASINOFF, B.B. *see* SCHAEFER, J.P.
HAWKSWORTH, G.M. & CHRYSTYN, H. Clinical pharmacy in primary care, 415
HAYASHI, N., KINOSHITA, H., YUKAWA, E. & HIGUCHI, S. Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production, 11
HEFTING, N.R. *see* SEABER, E.J.
HENDRICK, D.J. *see* DEVEREUX, G.
HENRY-MOWATT, J.S. *see* KEWN, S.
HERBEN, V.M.M., SCHELLENS, J.H.M., TEN BOKKEL HUININK, W.W., ROSING, H., VAN ZOMEREN, D.M., BEUSENBERG, F.B., ROSS, G. & BEIJNEN, J.H. A new oral dosage form of topotecan: bioavailability and effect of food co-administration, 630P
HICKS, A. *see* LUNNON, M.W.
HIGUCHI, S. *see* HAYASHI, N.
HILL, R.G. *see* LONGMORE, J.
HOEFNAGELS, W.H.L. *see* VAN KRAAIJ, D.J.W.
HOETELMANS, R.M.W. *see* BURGER, D.M.
HOETELMANS, R.M.W. *see* HUGEN, P.W.H.
HOFFMANN, R. *see* KIRCHNER, G.I.
HOGGARD, P.G. *see* KEWN, S.
HOL, C.W. *see* TEN HAVE, S.M.
HOLFORD, N.H.G. *see* ANDERSON, B.J.
HOOYMANS, P.M. *see* VAN DER KUY, P.-H.M.
HOSKINS, J.M., SHENFIELD, G.M. & GROSS, A.S. Relationship between proguanil metabolic ratio and *CYP2C19* genotype in a Caucasian population, 499
HOUGHTON, J. *see* BRACCHI, A.D.
HOUSE, F. *see* LUNNON, M.W.
HSU, A. *see* OUELLET, D.
HUGEN, P.W.H. *see* BURGER, D.M.
HUGEN, P.W.H., BURGER, D.M., BRINKMAN, K., KOOPMANS, P.P., HOETELMANS, R.M.W., MEENHORST, P.L. & MULDER, J.W. Salivary indinavir levels as a method to monitor compliance and predict plasma levels in HIV positive patients, 620P
HUGHES, S.G. Prescribing for the elderly patient: why do we need to exercise caution?, 531
HUITEMA, A.D.R., TIBBEN, M.M., KERBUSCH, T., RODENHUIS, S. & BEIJNEN, J.H. Simultaneous determination of thioTEPA, cyclophosphamide and some of their metabolites in plasma using capillary gas chromotography, 619P
HUNG, J. *see* TAYLOR, M.L.
HUPPERETZ, P.C. *see* WILKINSON, I.B.
HUSSAIN, F.N., AJJAN, R.A., MOUSTAFA, M., WEIR, N.W. & RILEY, S.A. Mesalazine release from a pH dependent formulation: effects of omeprazole and lactulose co-administration, 173
HUTCHINGS, A.D. *see* BRACCHI, A.D.
HUTCHINGS, A.D. *see* SHETTY, H.G.M.

IBÁNEZ, L. *see* LAPORTE, J.-R.
ILETT, K.F. *see* MAGGS, J.L.
ILSON, B. *see* TENERO, D.M.
ILTON, M.K. *see* TAYLOR, M.L.
IN'T VELD, B.A. *see* FEENSTRA, J.

JACKSON, P.R. *see* OATES, A.
JACKSON, S.K. *see* ELLIS, G.R.
JAEHDE, U. *see* SALEMING, W.
JÄGER, D. *see* BRUNNER, M.
JAILLON, P. *see* BLASCHKE, T.F.
JANSEN, R.W.M.M *see* VAN KRAAIJ, D.J.W.
JICK, H. *see* MYERS, M.W.
JODRELL, D.I. *see* ROSARIO, M.C.
JOHNSON, E.S. *see* WARRINGTON, S.
JOHNSON, M.A., VERPOOTEN, G.A., DANIEL, M.J., PLUMB, R., MOSS, J.,

VAN CAESBROECK, D. & DE BROE, M.E. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis, 21
JONKERS, R.E. & KOOPMANS, R.P. The pharmacokinetics and lymphocytopenic effect of methylprednisolone (MP) during pulse therapy in patients with lung fibrosis. A pilot study in five patients, 618P
JONKMAN, J.H.G. *see* SEABER, E.J.
JONKMAN, J.H.G. *see* PEETERS, P.A.M.
JORKASKY, D.K. *see* TENERO, D.M.
JOUBERT, P. & BOYD, A. How does a drug developer study a new drug in patients with liver disease? 352
JOVIC, R. *see* SALEMING, W.

KAGER, P.A. *see* SCHIPPER, H.G.
KAMALI, F. *see* BIRCH, D.
KAMALI, F. *see* BIRCH, D.
KAMINSKY, L.S. *see* FONTANA, R.J.
KANTOLA, T. *see* KIVISTÖ, K.T.
KARBWANG, J. *see* EZZET, F.
KASTELEIJNNOLST TRENITE, D.G.A. A comparison of lamotrigine and vigabatrin in the outpatient population of an epilepsy centre, 626P
KASTELEIJNNOLST TRENITE, D.G.A. *see* DE HAAN, G.J.
KELLY, P. *see* BIRCH, D.
KENNA, J.G. *see* RAMSAY, L.
KENNA, J.G. *see* SOMCHIT, N.
KERBUSCH, T. *see* HUITEMA, A.D.R.
KERGUERIS, M.F. *see* PAWLOTSKY, F.
KEWN, S., HOGGARD, P.G., HENRY-MOWATT, J.S., BARRY, M.G. & BACK, D.J. Enhanced activation of nucleoside analogues in the presence of hydroxyurea *in vitro*, 283P
KHAKOO, S., GLUE, P., GRELLIER, L., WELLS, B., BELL, A., DASH, C., MURRAY-LYON, I., LYPNYJ, D., FLANNERY, B., WALTERS, K. & DUSHEIKO, G.M. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions, 563
KHAN, S.Q., STRACHAN, F.E., MEGSON, I.L., MAZZEI, F.A., NEWBY, D.E., BUTLER, A.R. & WEBB, D.J. A comparison of the effects of RIG-200, a novel S-nitrosated glyco-amino acid, and sodium nitroprusside in the dorsal hand veins of health male subjects *in vivo*, 280P
KIELY, D.G., LEE, A.F.C., STRUTHERS, A.D. & LIPWORTH, B.J. Nitric oxide: an important role in the maintenance of systemic and pulmonary vascular tone in man, 263
KIMURA, M., UMEMURA, K., KOSUGE, K., NISHIMOTO, M, OHASHI, K. & NAKASHIMA, M. Attenuation by ACE inhibitor drugs of α-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity, 599
KINOSHITA, H. *see* HAYASHI, N.
KIRCHNER, G.I., FRANZKE, A., BUER, J., BEIL, M., PROBST-KEPPER, F., WITTKE, F., ÖVERMANN, K., LASSMANN, S., HOFFMANN, R., KIRCHNER, H., GANSER, A. & ATZPODIEN, J. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application, 5
KIRCHNER, H. *see* KIRCHNER, G.I.
KIVISTÖ, K.T., KANTOLA, T. & NEUVONEN, P.J. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin, 49
KLOTZ, U. *see* LI, G.
KLOTZ, U. *see* MÖRIKE, K.
KNAPP, M.J. *see* FONTANA, R.J.
KNEALE, B.J., CHOWIENCZYK, P.J. & RITTER, J.M. Actions of propranolol on noradrenaline-mediated vasoconstriction in forearm vasculature of men and women, 281P
KOBAYASHI, K. *see* NAKAJIMA, M.
KOOPMANS, P.P. *see* BURGER, D.M.
KOOPMANS, P.P. *see* HUGEN, P.W.H.
KOOPMANS, R. *see* SCHIPPER, H.G.
KOOPMANS, R.P. *see* JONKERS, R.E.
KOSUGE, K. *see* KIMURA, M.
KRAUWINKEL, W.J.J. *see* BURGGRAAF, J.
KREMER, J. *see* GODFREY, C.
KUROIWA, Y. *see* NAKAJIMA, M.

LA MANNA, C. *see* DRAGO, F.
LANG, D. *see* ELLIS, G.R.
LAPEYRE-MESTRE, M. *see* DESBOEUF, K.
LAPORTE, J.-R., VIDAL, X., BALLARÍN, E. & IBÁNEZ, L. Possible association between ocular chloramphenicol and aplastic anaemia – the absolute risk is very low, 181
LASSMANN, S. *see* KIRCHNER, G.I.
LAYTON, G. *see* PECK, R.W.
LAZZARI, P. *see* FOGARI, R.
LEE, A.F.C. *see* KIELY, D.G.
LENDERINK, A.W. *see* VAN DEN BEMT, P.M.L.A.
LENDERINK, A.W. *see* VAN ROON, E.N.
LEONARD, J.M. *see* OUELLET, D.
LEONE, A. *see* BUTLER, R.
LESIEUR, O. *see* ANNANE, D.
LEUFKENS, H.G.M. *see* VAN DEN BEMT, P.M.L.A.
LEWIS, M.J. *see* ELLIS, G.R.
LI, G., GONG, P.L., QIU, J., ZENG, F.-D. & KLOTZ, U. Stereoselective steady state disposition and action of propafenone in Chinese subjects, 441
LINDNER, J. *see* MCMANUS, P.
LINDUP, W.E. *see* HALIFAX, K.L.
LINDUP, W.E. *see* SHAH, I.A.
LIPSCOMB, G.R., WALLIS, N., ARMSTRONG, G. & REES, W.D.W. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study, 133
LIPWORTH, B.J. & CLARK, D.J. Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices, 45
LIPWORTH, B.J. *see* KIELY, D.G.
LIU, G. *see* REID, K.
LOCKE, C.S. *see* OUELLET, D.
LOFT, S. *see* HADERSLEV, K.V.
LOHMAN, J.J.H.M. *see* VAN DER KUY, P.-H.M.
LONGMORE, J., RAZZAQUE, Z., SHAW, D., DAVENPORT, A.P., MAGUIRE, J., PICKARD, J.D., SCHOFIELD, W.N. & HILL, R.G. Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT_{1B}-receptors, 577
LOONEN, A.J.M. *see* VEEN, G.J.
LUGT, CH.B. *see* PEETERS, P.A.M.
LUNNON, M.W., HICKS, A., HOUSE, F., OLSSON, P., PIKE, N., SUMNER, M.J., TAYLOR, I.W. & WATTS, I.S. A first evaluation in man of escalating single intravenous doses of glycoprotein IIb/IIIa receptor antagonist GR233548, 281P
LUSARDI, P. *see* FOGARI, R.
LYPNYJ, D. *see* KHAKOO, S.

MacCALUM, H. *see* WILKINSON, I.B.
MACDERMOT, J. *see* CHOUDHURY, R.P.
MAGGS, J.L. *see* PARK, B.K.
MAGGS, J.L. *see* BISHOP, L.P.D.
MAGGS, J.L. *see* BOOCOCK, D.J.
MAGGS, J.L. *see* NAISBITT, D.J.
MAGGS, J.L., BATTY, K.T., ILETT, K.F., EDWARDS, G. & PARK, B.K. Isomerization in human urine of a glucuronide of the antimalarial endoperoxide drug dihydroartemisin, 293P
MAGUIRE, J. *see* LONGMORE, J.
MALCOLM, J. *see* BAILEY, D.G.
MALIEPAARD, M. *see* MEERUM TER WOGT, J.M.
MALINGRE, M.M., MEERUM TER WOGT, J.M., SCHELLENS, J.H.M., DUCHIN, K., ROSING, H. & BEIJNEN, J.H. Co-administration of cyclosporin A interferes with paclitaxel metabolism in humans, 626P
MALLARD, N. *see* WARRINGTON, S.
MANN, R.D. Prescription-event monitoring — recent progress and future horizons, 195
MANN, R.D. *see* MARTIN, R.M.
MARINO, A. *see* DRAGO, F.
MARINO, V. *see* DRAGO, F.
MARLEY, J. *see* MCMANUS, P.
MARTIN, D.E. *see* TENERO, D.M.
MARTIN, R.M., BISWAS, P.N., FREEMANTLE, S.N., PEARCE, G.L. & MANN, R.D. Age and sex

distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies, 505
MATHER, L.E., WOODHOUSE, A., WARD, M.E., FARR, S.J., RUBSAMEN, R.A. & ELTHERINGTON, L.G. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery, 37
MATHIEU, B. *see* ANNANE, D.
MAURO, K. *see* ADEOYIN, A.
MAZZEI, F.A. *see* KHAN, S.Q.
McCULLOCH, P.G. *see* SHAH, I.A.
McGRATH, J.C. Use of models to study vascular aspects of heart failure, 360
McKENNA, W.J. Genetic aspects of heart failure, 361
McKILLOP, D. *see* WILD, M.J.
McLEOD, H.L. *see* RIDGE, S.A.
McMANUS, P., MARLEY, J., BIRKETT, D.J. & LINDNER, J., Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia, 409
McMURRAY, J. Recent trials in chronic heart failure (CHF) 360
McNEILL, K.L. *see* FONTANA, L.
MEENHORST, P.L. *see* BURGER, D.M.
MEENHORST, P.L. *see* HUGEN, P.W.H.
MEERUM TER WOGT, J.M. *see* MALINGRE, M.M.
MEERUM TER WOGT, J.M., BEIJNEN, J.H., TEN BOKKEL HUININK, W.W., ROSING, H., VAN
MEERUM TER WOGT, J.M., BEIJNEN, J.J., TEN BOKKEL HUININK, W.W., MALIEPAARD, M., TIBBEN, M., WELBANK, H., GROENEWEGEN, G. & SCHELLENS, J.H.M. Phase I and pharmacologic study of SPI-77, a new liposomal encapsulated formulation of
MEGSON, I.L. *see* KHAN, S.Q.
MEINEKE, I. *see* FREUDENTHALER, S.
MERKUS, F.W.H.M. *see* VAN DER KUY, P.-H.M.
MIGET, N. *see* PATAT, A.
MIKUS, G. *see* MÖRIKE, K.
MILLER, A.K. *see* TENERO, D.M.
MILLER, K. *see* GODFREY, C.
MINTO, C. & SCHNIDER, T. Expanding clinical applications of population pharmacodynamic modelling, 321
MISSO, N.L.A. *see* TAYLOR, M.L.
MONTASTRUC, J.-L. *see* DESBOEUF, K.
MORGAN, D.J. *see* NAWARATNE, S.
MÖRIKE, K., PLATTEN, H.P., MIKUS, G. & KLOTZ, U. Variability in the frequency of cytochrome P450–2D6 (CYP2D6) deficiency, 87
MORRIS, A.D. *see* BUTLER, R.
MORRIS, A.D. *see* UEDA, S.
MORRIS, R.G., BLACK, A.B., HARRIS, A.L., BATTY, A.B. & SALLUSTIO, B.C. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service, 547
MOSS, J. *see* JOHNSON, M.A.
MOUSTAFA, M. *see* HUSSAIN, F.N.
MOYOU, R.S. *see* PEETERS, P.A.M.
MUCKLOW, J.C. A manual of adverse drug interactions (Book review), 275
MUGELLINI, A. *see* FOGARI, R.
MULDER, J.W. *see* BURGER, D.M.
MULDER, J.W. *see* HUGEN, P.W.H.
MULL, R. *see* EZZET, F.
MÜLLER, M. *see* BRUNNER, M.
MURRAY, G.D. The design and analysis of sequential clinical trials (Book review), 413
MURRAY, L. Sample size tables for clinical studies (Book review), 616
MURRAY-LYON, I. *see* KHAKOO, S.
MUSCARÁ, M.N. *see* DA SILVA, C.M.F.
MYERS, M.W. & JICK, H. Terfenadine and risk of acute liver disease, 251

NACKE, A. *see* REICHEL, C.
NAISBITT, D.J. *see* WILLIAMS, D.P.
NAISBITT, D.J., VILAR, J., WILKINS, E.G.L., BARRY, M. PIRMOHAMED, M. & PARK, B.K. Plasma cysteine deficiency in HIV infected patients: implications for sulphamethazole hypersensitivity, 285P
NAISBITT, D.J., WILLIAMS, D.P., PIRMOHAMED, M. & PARK, B.K. Amodiaquine-induced neutrophil apoptosis, 292P
NAISBITT, D.J., WILLIAMS, D.P., MAGGS, J.L., PIRMOHAMED, M. & PARK, B.K. Metabolism-dependent neutrophil toxicity of amodiaquine: a comparison with related antimalarial drugs, 291P
NAKAJIMA, M., KOBAYASHI, K., SHIMADA, N., TOKUDOME, S., YAMAMOTO, T. & KUROIWA, Y. Involvement of CYP1A2 in mexiletine metabolism, 55
NAKASHIMA, M. *see* KIMURA, M.
NAWARATNE, S., BRIEN, J.E., SEEMAN, E., FABINY, R., ZALCBERG, J., COSOLO, W., ANGUS, P. & MORGAN, D.J. Relationships among liver and kidney volumes, lean body mass and drug clearance, 447
NEUVONEN, P.J. *see* KIVISTÖ, K.T.
NEWBY, D.E. *see* KHAN, S.Q.
NIEMEYER, M.G. *see* TEN HAVE, S.M.
NIMMO, W. *see* BARDSLEY, H.
NISHIMOTO, M. *see* KIMURA, M.

O'CONNOR-SEMMES, R. *see* PALMER, J.L.
O'KANE, K. Streetwise drugwise (Book review), 615
O'NEILL, P.M. *see* PARK, B.K.
O'NEILL, P.M. *see* BISHOP, L.P.D.
OATES, A., JACKSON, P.R., AUSTIN, C.A. & CHANNER, K.S. A new regimen for start warfarin therapy in out-patients, 157
OHASHI, K. *see* KIMURA, M.
OLIVE, G. *see* FABRE, E.
OLSSON, P. *see* LUNNON, M.W.
OOSTELBOS, M.C.J.M. *see* VEEN, G.J.
OOSTERHUIS, B. *see* PEETERS, P.A.M.
ORLANDO, R., FLOREANI, M., PADRINI, R. & PALATINI, P. Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: equivalence of systemic and renal clearances as glomerular filtration markers, 605
ORME, M. Drugs and human lactation (Book review), 91
OSBORNE, C.M. *see* PEETERS, P.A.M.
OTTO, C., PARHOFER, K.G., RITTER, M.M., RICHTER, W.O. & SCHWANDT, P. Effects of acipimox on haemorpheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia, 473
OUELLET, D., HSU, A., QIAN, J., LOCKE, C.S., EASON, C.J., CAVANAUGH, J.H., LEONARD, J.M. & GRANNEMAN, G.R. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers, 111
OUWELS, L.H.R. *see* VAN KRAAIJ, D.J.W.
ÖVERMANN, K. *see* KIRCHNER, G.I.

PADRINI, R. *see* ORLANDO, R.
PALATINI, P. *see* ORLANDO, R.
PALMER, J.L. *see* DE ALWIS, D.P.
PALMER, J.L., BARRINGTON, P. & O'CONNOR-SEMMES, R. Safety, tolerability and pharmacokinetics of the NK_1 receptor antagonist GR205171 in healthy male volunteers, 298P
PALMER, J.L., FUMOLEAU, P., BRYSSINE, B., DIEMUNSCH, P., SCHOEFFLER, P., SPRAGGS, C. & GRAHAM, E. Preliminary pharmacokinetics of the NK_1 receptor antagonist GR205171 in patients with chemtherapy-induced or post operative nausea and vomiting, 297P
PANFILOV, V. *see* UEDA, S.
PARHOFER, K.G. *see* OTTO, C.
PARK, B.K. *see* BISHOP, L.P.D.
PARK, B.K. *see* BOOCOCK, D.J.
PARK, B.K. *see* GILL, H.J.
PARK, B.K. *see* MAGGS, J.L.
PARK, B.K. *see* NAISBITT, D.J.
PARK, B.K. *see* WILLIAMS, D.P.
PARK, B.K., O'NEILL, P.M., MAGGS, J.L. & PIRMOHAMED, M. Safety assessment of peroxide antimalarials: clinical and chemical perspectives, 521
PARK, B.K. *see* PIRMOHAMED, M.
PARK, B.K. Prediction of drug-induced hepatotoxicity, 357
PATAT, A., TROCHERIE, S., MIGET, N., ENSLEN, M., GANDON, J.M. & ROSENZWEIG, P. Effects of a slow release formulation of caffeine on EEG, pscyhomotor and cognitive functions in sleep-deprived health volunteers, 285P
PAWLOTSKY, F., THOMAS, A., KERGUERIS, M.F., DEBILLON, T. & ROZE, J.C. Constant rate infusion of

vancomycin in premature neonates: a new dosage schedule, 163
PEARCE, G.L. *see* MARTIN, R.M.
PECK, R.W. *see* SEABER, E.J.
PECK, R.W., WOOTTON, R., WIGGS, R., LAYTON, G. & POSNER, J. Effect of food and gender on the pharmacokinetics of tucaresol in healthy volunteers, 83
PEDRAZZOLI, J. *see* DA SILVA, C.M.F.
PEETERS, P.A.M., BEUKEMA, J., OOSTERHUIS, B., SMEETS, F.W.M., MOYOU, R.S., THIETCHE, F., OSBORNE, C.M., THUMA, P.E., BHAT, G.J., BIEMBA, G., SHAKANKALE, G.M., JONKMAN, J.H.G. & LUGT, CH.B. -arteether (Artecef® paediatric): efficacy and safety in African children with cerebral malaria, 629
PENG, Y. *see* SCHAEFER, J.P.
PETERSON, D.W. *see* BRADY, P.A.
PHIBOONBANAKIT, D., BARRY, M.G. & BACK, D.J. Quantification of intracellular zidovudine triphosphate by enzymatic assay, 294P
PICKARD, J.D. *see* LONGMORE, J.
PICKKERS, P. *see* DE HOON, J.N.J.M.
PIECHAUD, J-F. *see* FABRE, E.
PIEGLER, E. *see* BRUNNER, M.
PIKE, N. *see* LUNNON, M.W.
PIRMOHAMED, M. & PARK, K. Are methods of detecting drug-induced hepatotoxicity adequate? 355
PIRMOHAMED, M. *see* PARK, B.K.
PIRMOHAMED, M. *see* GILL, H.J.
PIRMOHAMED, M. *see* NAISBITT, D.J.
PIRMOHAMED, M. *see* WILLIAMS, D.P.
PLATTEN, H.P. *see* MÖRIKE, K.
PLUMB, R. *see* JOHNSON, M.A.
POGGI, L. *see* SPEIRS, C.J.
POLIMENO, N.C. *see* DA SILVA, C.M.F.
PONS, G. *see* FABRE, E.
POOLE-WILSON, P. Future therapies, 362
PORT, R.E., DING, R.W., FIES, T. & SCHÄRER, K. Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia, 461
POSNER, J. *see* PECK, R.W.
POULSEN, H.E. *see* HADERSLEV, K.V.
PROBST-KEPPER, M. *see* KIRCHNER, G.I.
PROFIT, L., BROOKS, B., WILLIAMS, D.P. & BACK, D.J. Modulation of P-glycoprotein function in human peripheral mononuclear cells by saquinavir, 295P
PÜCHLER, K., SIERAKOWSKI, B. & ROOTS, I. Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients, 363
PYM, A.S. *see* CHURCHILL, D.R.

QIAN, J. *see* OUELLET, D.
QIU, J. *see* LI, G.

RADEMAKER, M.V. *see* DE HAAN, G.J.
RAMSAY, L., BARNES, S., GARDINER, I., ELIASSON E. & KENNA, J.G. Identification by immunoprecipitation of novel halothane-induced protein antigens recognized by antibodies from patients with halothane hepatitis, 303P
RAMSAY, L.A. *see* SOMCHIT, N.
RAPHAEL, J.C. *see* ANNANE, D.
RAWLINS, M.D. What does a doctor need to know about a new drug before it is administered to a patient? What information does he need about liver disease? 351
RAZZAQUE, Z. *see* LONGMORE, J.
REES, W.D.W. *see* LIPSCOMB, G.R.
REIBALDI, A. *see* DRAGO, F.
REICHEL, C., SKODRA, T., NACKE, A., SPENGLER, U. & SAUERBRUCH, T. The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans, 535
REID, K., SCIBERRAS, D.G., GERTZ, B.J., REINHARDT, R.R., LIU, G., GOLDING, J.F. & STOTT, J.R.R. Comparison of a neurokinin-1 antagonist, L-758,298, and scopolamine with placebo in the prevention of motion-induced nausea in man, 282P
REIDENBERG, M.M. & BRECKENRIDGE, A. Summary and conclusion, 358
REIDENBURG, M. Chairman's introduction, 351
REIMCHE, L. *see* SCHAEFER, J.P.
REINHARDT, R.R. *see* REID, K.
REY, E. *see* FABRE, E.
RICHELL, R. *see* TOWARD, T.
RICHTER, W.O. *see* OTTO, C.
RIDGE, S.A., SLUDDEN, J., BROWN, O., ROBERTSON, L., WEI, X., SAPONE, A., FERNANDEZ-SALGUERO, P.M., GONZALEZ, F.J., VREKEN, P., VAN KUILENBURG, A.B.P., VAN GENNIP, A.H. & McLEOD, H.L. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects, 151
RILEY, S.A. *see* HUSSAIN, F.N.
RITTER, J.M. *see* BRETT, S.E.
RITTER, J.M. *see* FONTANA, L.
RITTER, J.M. *see* KNEALE, B.J.
RITTER, M.M. *see* OTTO, C.
ROBERTS, M.S. *see* CROSS, S.E.
ROBERTSON, L. *see* RIDGE, S.A.
RODENHUIS, S. *see* HUITEMA, A.D.R.
ROLFE, L. *see* WARRINGTON, S.
ROOTS, I. *see* PÜCHLER, K.
ROSARIO, M.C., THOMSON, A.H., JODRELL, D.I., SHARP, C.A. & ELLIOTT, H.L. Population pharmacokinetics of gentamicin in patients with cancer, 229
ROSENZWEIG, P. *see* PATAT, A.
ROSING, H. *see* HERBEN, V.M.M.
ROSING, H. *see* MALINGRE, M.M.
ROSING, H. *see* MEERUM TER WOGT, J.M.
ROSS, G. *see* HERBEN, V.M.M.
ROTBLAT, F. What information does the drug regulator presently require before allowing a new drug to be used in patients with liver disease? 352
ROUTLEDGE, P.A. *see* BRACCHI, A.D.
ROUTLEDGE, P.A. *see* SHETTY, H.G.M.
ROUTLEDGE, R.A., SHETTY, H.G.M., WHITE, J.P. & COLLINS, P. Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism, 343
ROWKINS, S. *see* WARRINGTON, S.
ROZE, J.C. *see* PAWLOTSKY, F.
RUBSAMEN, R.A. *see* MATHER, L.E.
RUSSEL, F.G.M. *see* DEKKER, S.

SALEMING, W., JAEHDE, U., SCHONING, H. & SIEGERT, W. O-demethylation of etoposide: a potential source of drug interactions, 627P
SALEMING, W., JOVIC, R., AMREIN, R. & DINGEMANSE, J. Tolerability, pharmacokinetics and pharmacodynamics of combined moclobemide and diazepam in healthy subjects, 628P
SALLUSTIO, B.C. *see* MORRIS, R.G.
SAPONE, A. *see* RIDGE, S.A.
SAUERBRUCH, T. *see* REICHEL, C.
SCHABER, G., STEVENS, I., GAERTNER, H.J., DIETZ, K. & BREYER-PFAFF, U. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: plasma protein binding and renal clearance, 453
SCHAEFER, J.P., TAM, Y., HASINOFF, B.B., TAWFIK, S., PENG, Y., REIMCHE, L. & CAMPBELL, N.R.C. Ferrous sulfate interacts with captopril, 377
SCHÄRER, K. *see* PORT, R.E.
SCHEININ, H. *see* WAKELKAMP, M.
SCHELLENS, J.H.M. *see* HERBEN, V.M.M.
SCHELLENS, J.H.M. *see* MALINGRE, M.M.
SCHELLENS, J.H.M. *see* MEERUM TER WOGT, J.M.
SCHIPPER, H.G., BUTTER, J.J., KAGER, P.A., VAN BOXTEL, C.J. & KOOPMANS, R. The effect of cimetidine and dose increase on concentration of albendazole-sulphoxide in healthy subjects, 618P
SCHMID, R. *see* BRUNNER, M.
SCHMIEDBERGER, A. *see* BRUNNER, M.
SCHNIDER, T. *see* MINTO, C.
SCHOEFFLER, P. *see* PALMER, J.L.
SCHOEMAKER, H.C. *see* BURGGRAAF, J.
SCHOFIELD, W.N. *see* LONGMORE, J.
SCHOLZE, J. & STAPFF, M. Start of therapy with the angiotensin II antagonist losartan after immediate switch from pretreatment with an ACE inhibitor, 169

© 1998 Blackwell Science Ltd

SCHONING, H. *see* SALEMING, W.
SCHREEB, K.-H. *see* FREUDENTHALER, S.
SCHWAGMEIER, R., ALINCIC, S. & STRIEBEL, H.W. Midazolam pharmacokinetics following intravenous and buccal administration, 203
SCHWANDT, P. *see* OTTO, C.
SCIBERRAS, D.G. *see* REID, K.
SEABER, E.J., PECK, R.W., SMITH, D.A., ALLANSON, J., HEFTING, N.R., VAN LIER, J.J., SOLLIE, F.A.E., WEMER, J. & JONKMAN, J.H.G. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers, 433
SEBILLE, V. *see* ANNANE, D.
SEEMAN, E. *see* NAWARATNE, S.
SESSA, C. *see* STANKE, F.
SHAH, I.A., LINDUP, W.E. & McCULLOCH, P.G. Freundlich and Langmuir isotherms as descriptors of mitomycin C adsorption to activated charcoal, 299P
SHAH, I.A., LINDUP, W.E. & McCULLOCH, P.G. The effect of protein on the adsorption of mitomycin C to activated charcoal, 300P
SHAKANKALE, G.M. *see* PEETERS, P.A.M.
SHARP, C.A. *see* ROSARIO, M.C.
SHAW, D. *see* LONGMORE, J.
SHENFIELD, G.M. Drug development for women (Book review), 521
SHENFIELD, G.M. *see* HOSKINS, J.M.
SHENFIELD, G.M. Therapeutic drug monitoring beyond 2000, 93
SHETTY, H.G.M. *see* ROUTLEDGE, R.A.
SHETTY, H.G.M., BUSS, D.C., HARRY, F., HUTCHINGS, A.D. & ROUTLEDGE, P.A. The effect of oral cholestyramine on the pharmacokinetics of warfarin enantiomers, 290P
SHIMADA, N. *see* NAKAJIMA, M.
SHYU, W.C. *see* VACHHARAJANI, N.N.
SIEGERT, W. *see* SALEMING, W.
SIERAKOWSKI, B. *see* PÜCHLER, K.
SIMONS, K.A. *see* VAN DEN BEMT, P.M.L.A.
SKODRA, T. *see* REICHEL, C.
SLUDDEN, J. *see* RIDGE, S.A.
SMAIL, S.A. *see* BRACCHI, A.D.
SMEETS, F.W.M. *see* PEETERS, P.A.M.
SMITH, D.A. *see* SEABER, E.J.
SMITH, R.A. *see* VACHHARAJANI, N.N.
SMITS, P. *see* DE HOON, J.N.J.M.
SMITS, P. *see* DEKKER, S.
SMYTH, A. The paediatric lung (Book review), 615
SOLLIE, F.A.E. *see* SEABER, E.J.
SOMCHIT, N., RAMSAY, L.A., KENNA, J.G. & CALDWELL, J. Glucuronidation mediates hepatic protein adduct formation from diclofenac, but not ibuprofen, in rats: a potential mechanism of hepatotoxicity, 304P
SONNE, J. *see* HADERSLEV, K.V.
SOUSA, S.S. *see* DA SILVA, C.M.F.
SPEIRS, C.J., WAGNIART, F., POGGI, L. Perindopril postmarketing surveillance: a twelve-month study in 47 351 hypertensive patients, 63
SPENCE, J.D. *see* BAILEY, D.G.
SPENGLER, U. *see* REICHEL, C.
SPRAGGS, C. *see* PALMER, J.L.
STANKE, F., DEVILLIER, P, BRÉANT, D., CHEVANON, O., SESSA, C., BRICCA, G. & BESSARD, G. Frusemide inhibits angiotensin II-induced contraction on human vascular smooth muscle, 571
STAPFF, M. *see* SCHOLZE, J.
STAPPERS, J.L.M. *see* DE STOPPELAAR, F.M.
STEEDS, R.P. & CHANNER, K.S. Recent advances in the management of unstable angina and non-Q-wave myocardial infarction, 335
STEEGERS, E.A.P. *see* DEKKER, S.
STEVENS, I. *see* SCHABER, G.
STOLK, L.M.L. *see* DE STOPPELAAR, F.M.
STOTT, D.J. Drug therapy in old age (Book review), 413
STOTT, J.R.R. *see* REID, K.
STRACHAN, F.E. *see* KHAN, S.Q.
STRICKER, B.H.CH. *see* FEENSTRA, J.
STRIEBEL, H.W. *see* SCHWAGMEIER, R.
STRUTHERS, A.D. *see* BUTLER, R.
STRUTHERS, A.D. *see* KIELY, D.G.
STRUTHERS, A.D. *see* YEE, K.M.
SUMNER, M.J. *see* LUNNON, M.W.
SWART, M. *see* MEERUM TER WOGT, J.M.
SWEENEY, K. *see* GODFREY, C.

TAM, Y. *see* SCHAEFER, J.P.
TANG, B.K. *see* FONTANA, R.J.
TASCO, F. *see* BILLAUD, E.M.
TAWFIK, S. *see* SCHAEFER, J.P.
TAYLOR, I.W. *see* LUNNON, M.W.
TAYLOR, M.L., ILTON, M.K., MISSO, N.L.A., WATKINS, D.N., HUNG, J. & THOMPSON, P.J. The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils, 139
TELLINGEN, O., SWART, M., DUCHIN, K. & SCHELLENS, J.H.M. Co-administration of cyclosporin A (CsA) enables oral therapy with paclitaxel, 624P
TEN BOKKEL HUININK, W.W. *see* HERBEN, V.M.M.
TEN BOKKEL HUININK, W.W. *see* MEERUM TER WOGT, J.M.
TEN HAVE, S.M., CLEOPHAS, T.J., HOL, C.W., VAN DER MEULEN, J., NIEMEYER, M.G. & DE PLANQUE, B.A. A randomized placebo-controlled study of loop-diuretics in patients with essential hypertension, the BUFUL clinical study report, 628P
TENERO, D.M., MARTIN, D.E., MILLER, A.K., ILSON, B., BOIKE, S.C., ZARIFFA, N. & JORKASKY, D.K. Effect of age and gender on the pharmacokinetics of eprosartan, 267
TER BERG, J.W.M. *see* VAN DER KUY, P.-H.M.
THIETCHE, F. *see* PEETERS, P.A.M.
THOMAS, A. *see* PAWLOTSKY, F.
THOMPSON, P.J. *see* TAYLOR, M.L.
THOMSON, A.H. *see* ROSARIO, M.C.
THUMA, P.E. *see* PEETERS, P.A.M.
TIBBEN, M. *see* MEERUM TER WOGT, J.M.
TIBBEN, M.M. *see* HUITEMA, A.D.R.
TINER, R. *see* DOYLE, K.
TINGLE, M.D. *see* GILL, H.J.
TOKUDOME, S. *see* NAKAJIMA, M.
TOLL, P.J.M.M. *see* VEEN, G.J.
TOWARD, T., RICHELL, R., GREWAL, H.K., BYE, C. & BABER, N. Applanation tonometry: reproducibility and repeatability of pulse wave forms and pulse wave velocity using the sphygmocor system, 286P
TOWARD, T., RICHELL, R., GREWAL, H.K., BYE, C. & BABER, N. Applanation tonometry: variation in pulse wave forms as a result of stimulation, 287P
TROCHERIE, S. *see* PATAT, A.
TSIKAS, D. *see* BODE-BÖGER, S.M.
TUCKER, G.T. Alteration of drug disposition in liver impairment, 355

UEDA, S., DONNELLY, R., PANFILOV, V., MORRIS, A.D. & ELLIOTT, H.L. Lacidipine: effects on vascular pressor responses throughout the dosage interval in normotensive subjects, 127
UMEMURA, K. *see* KIMURA, M.

VACHHARAJANI, N.N., SHYU, W.C., SMITH, R.A. & GREENE, D.S. The effects of age and gender on the pharmacokinetics of irbesartan, 612
VAN AGTMAEL, M.A., GUPTA, V. & VAN BOXTEL, C.J. Grapefruit juice increases the bioavailability of artemether, 629P
VAN BORTEL, L.M.A.B. *see* DE HOON, J.N.J.M.
VAN BOXTEL, C.J. *see* SCHIPPER, H.G.
VAN BOXTEL, C.J. *see* VAN AGTMAEL, M.A.
VAN CAESBROECK, D. *see* JOHNSON, M.A.
VAN DEN BEMT, P.M.L.A., EGBERTS, A.C.G., LENDERINK, A.W., VERZIJL, J.M., SIMONS, K.A., VAN DER POL, W.S.C.J.M. & LEUFKENS, H.G.M. Reporting of adverse drug reactions in hospital — a comparison of doctors, nurses and patients as sources of reports, 619P
VAN DEN BERG, P.B. *see* VAN DIJK, K.N.
VAN DER KUY, P.-H.M., LOHMAN, J.J.H.M., HOOYMANS, P.M., TER BERG, J.W.M. & MERKUS,

F.W.H.M. Pharmacokinetics of intranasal formulations of dihydroergotamine, 623P
VAN DER LINDEN, P.D. *see* FEENSTRA, J.
VAN DER MEULEN, J. *see* TEN HAVE, S.M.
VAN DER MEULEN, J., VAN DER SLUIJS, J.P., CLEOPHAS, T.J. & ZWINDERMAN, A.H. Replacement of ACE-inhibitors by AII-receptor antagonists in hypertensive patients with type II diabetes mellitus: metabolic and haemodynamic consequences, 630P
VAN DER POL, W.S.C.J.M. *see* VAN DEN BEMT, P.M.L.A.
VAN DER SLUIJS, J.P. *see* VAN DER MEULEN, J.
VAN DIJK, K.N., DE VRIES, C.S., VAN DEN BERG, P.B., DIJKEMA, A.M., BROUWERS, J.R.B.J. & DE JONG-VAN DEN BERG, L.T.W. Constipation as an adverse effect of drug use in nursing home patients: an overestimated risk, 255
VAN GENNIP, A.H. *see* RIDGE, S.A.
VAN HAARST, A.D. *see* BURGGRAAF, J.
VAN KRAAIJ, D.J.W., JANSEN, R.W.M.M, GO, I.H., BOUWELS, L.H.R., HOEFNAGELS, W.H.L. & GRIBNAU, F.W.J. A randomized placebo-controlled trial of frusemide withdrawal in elderly heart failure patients with preserved left ventricular
VAN KRAAIJ, D.J.W., JANSEN, R.W.M.M., BOUWELS, L.H.R. & HOEFNAGELS, W.H.L. Postprandial blood pressure reductions in elderly patients with diastolic heart failure improve following frusemide withdrawal, 625P
VAN KRAAIJ, D.J.W., JANSEN, R.W.M.M., DE GIER, J.J., GRIBNAU, F.W.J. & HOEFNAGELS, W.H.L. Prescription patterns of diuretics in Dutch community-dwelling elderly patients, 403
VAN KUILENBURG, A.B.P. *see* RIDGE, S.A.
VAN LIER, J.J. *see* SEABER, E.J.
VAN ROON, E.N., EGBERTS, A.C.G., VERZIJL, J.M. & LENDERINK, A.W. Patterns of switching and stopping initial highly-active antiretroviral therapy (HAART) in a cohort of Dutch HIV-seropositive patients, 621P
VAN TELLINGEN, O. *see* MEERUM TER WOGT, J.M.
VAN THOOR, C.J. *see* WILKINSON, I.B.
VAN ZOMEREN, D.M. *see* HERBEN, V.M.M.
VAUZELLE-KERVROEDAN, F. *see* FABRE, E.
VEEN, G.J., OOSTELBOS, M.C.J.M., TOLL, P.J.M.M. & LOONEN, A.J.M. Effect of blood collection tubes on tricyclic antidepressant blood levels, 631P
VERMEIJ, T.A.C. *see* EDELBROEK, P.M.
VERPOOTEN, G.A. *see* JOHNSON, M.A.
VERZIJL, J.M. *see* VAN DEN BEMT, P.M.L.A.
VERZIJL, J.M. *see* VAN ROON, E.N.
VIDAL, X. *see* LAPORTE, J.-R.
VILAR, J. *see* NAISBITT, D.J.
VREKEN, P. *see* RIDGE, S.A.

WAGNIART, F., *see* SPEIRS, C.J.
WAKELKAMP, M., ALVÁN, G., SCHEININ, H. & GABRIELSSON, J. The influence of drug input rate on the development of tolerance to frusemide, 479
WALLIS, N. *see* LIPSCOMB, G.R.
WALTERS, K. *see* KHAKOO, S.
WARD, M E. *see* MATHER, L.E.
WARRINGTON, S., BOYCE, M., ROLFE, L., CLARKE, A., MALLARD, N. & JOHNSON, E.S. Higher availability of selegiline from Zydis® than Deprenyl® formulations does not lead to increased potentiation of the pressor response to oral tyramine, 284P
WARRINGTON, S., BOYCE, M., ROLFE, L., CLARKE, A., MALLARD, N., ROWKINS, S. & JOHNSON, E.S. Are the metabolites of selegiline, rather than the parent compound, responsible for the potentiation of the pressor resonse to oral tyramine?, 297P
WATKINS, D.N. *see* TAYLOR, M.L.
WATKINS, P.B. *see* FONTANA, R.J.
WATSON, N. *see* BARDSLEY, H.
WATTS, I.S. *see* LUNNON, M.W.
WEBB, D.J. *see* KHAN, S.Q.
WEBB, D.J. *see* WILKINSON, I.B.
WEBER, J.N. *see* CHURCHILL, D.R.
WEI, X. *see* RIDGE, S.A.
WEIR, N.W. *see* HUSSAIN, F.N.
WELBANK, H. *see* MEERUM TER WOGT, J.M.
WELLER, C. *see* BRADY, P.A.
WELLS, B. *see* KHAKOO, S.
WEMER, J. *see* SEABER, E.J.
WHITE, I.N.H. *see* BOOCOCK, D.J.
WHITE, J.P. *see* ROUTLEDGE, R.A.
WHITE, M. *see* BIRCH, D.
WIGGS, R. *see* PECK, R.W.
WILD, M.J., BUTTERS, C.J. & McKILLOP, D. Determination of the human hepatic cytochrome P450 isozymes involved in zolmitriptan and *N*-desmethyl zolmitriptan metabolism *in vitro*, 290P
WILKINS, E.G.L. *see* NAISBITT, D.J.
WILKINSON, I.B., HUPPERETZ, P.C., VAN THOOR, C.J., MacCALUM, H., COCKCROFT, J.R. & WEBB, D.J. Acute hyperglycaemia reduces central arterial pressure in healthy subjects, 289P
WILKS, M. *see* BRADY, P.A.
WILLIAMS, D.P. *see* PROFIT, L.
WILLIAMS, D.P. *see* NAISBITT, D.J.
WILLIAMS, D.P., NAISBITT, D.J., PIRMOHAMED, M. & PARK, B.K. Clozapine induces neutrophil apoptosis by two concentration-dependent pathways: implications for agranulocytosis, 282P
WILLIAMS, K.M. *see* CAMPBELL, T.J.
WILTSHIRE, H.R. *see* HALIFAX, K.L.
WITTKE, F. *see* KIRCHNER, G.I.
WOODHOUSE, A. *see* MATHER, L.E.
WOODS, F.J. *see* BRACCHI, A.D.
WOOLF, T.F. *see* FONTANA, R.J.
WOOLLARD, G.A. *see* ANDERSON, B.J.
WOOTTON, R. *see* PECK, R.W.
WOUTERSE, A.C. *see* DEKKER, S.
WRIGHT, D.J. *see* AL-RASHED, S.A.
WRIGHT, D.J., AYKROYD, R.G. & CHRYSTYN H. Rating clinical pharmacy interventions by clinical panels: which health professionals should be included?, 278P

YAMAMOTO, T. *see* NAKAJIMA, M.
YEE, K.M. & STRUTHERS, A.D. Endogenous angiotensin II and baroreceptor dysfunction: a comparative study of losartan and enalapril in man, 583
YUKAWA, E. *see* HAYASHI, N.

ZALCBERG, J. *see* NAWARATNE, S.
ZARIFFA, N. *see* TENERO, D.M.
ZENG, F.-D. *see* LI, G.
ZOPPI, A. *see* FOGARI, R.
ZWINDERMAN, A.H. *see* VAN DER MEULEN, J.

© 1998 Blackwell Science Ltd

SUBJECT INDEX

This index was compiled from the keywords

α-adrenoceptor, 599
α-hydroxytamoxifen, 296P
ACE inhibitor, 363
ACE inhibitors, 630P
AII receptor antagonists, 630P
Acetominophen, 237
Acetylcholine, 517
Adaptation, 133
Adrenal function, 589
Adverse drug reaction monitoring, 63
Adverse drug reactions, 279P, 505, 619P
Adverse effects, 255
African children, 629P
Age, 267, 505, 612
Agranulocytosis, 282P
Airway responsiveness, 79
Albendazole-sulphoxide, 618P
Alcohol, 278P, 301P
Alzheimer's disease, 221
Ambulatory blood pressure monitoring, 169
Amodiaquine, 292P
Analysis, 547
Angiotensin, 599
Angiotensin II, 571, 583
Angiotensin II receptor antagonist, 267
Angiotensin antagonism, 169
Angiotensin converting enzyme inhibitor, 599
Anti-epileptic drugs, 185
Antiarrhythmic drugs, 307
Anticoagulation, 157
Anticonvulsant, 547
Antihistamines, 251
Antimalarial, 293P
Antipyrine clearance, 447
Antiretroviral therapy, 621P
Aplastic anaemia, 181
Applanation tonometry, 286P, 287P
Arteflene, 293P
Artemether, 553, 629P
Artemisinin, 521
Aspirin, 139
Asthma, 79
Atrial fibrillation, 157

β-arteether, 629P
Baroreceptor, 583
Beclomethasone, 207
Benflumeto, 553
Bias, 147
Bioavailability, 37, 433, 553, 629P, 630P
Blood collection tubes, 631P
Blood donors, 176
Bolus i.v. injection, 605
Book review: A manual of adverse drug interactions, 275
Book review: Drug therapy in old age, 413
Book review: Drug development for women 520
Book review: Drugs and human lactation 91
Book review: Medical pharmacology at a glance 91
Book review: Sample size tables for clinical trials 616
Book review: Streetwise Drugwise—a layman's guide 615
Book review: The design and analysis of sequential 413
Book review: The paediatric lung 615
Buccal, 203
BUFUL clinical study, 628P
Bufuralol, 55, 295P

CYP2C19, 499
CYP2D6, 55, 295P
CYP3A4, 101, 535
Caffeine, 221, 285P
Calcitonin gene related peptide, 621P
Calcium antagonists, 88
Cancer, 229
Captopril, 169, 377
Cardiac catheterisation, 395
Cardiovascular function, 245
cDNA expressed microsomes, 55
Central arterial pressure, 289P
Cerebrospinal fluid, 237
Charcoal, activated, 299P, 300P
Chloramphenicol, 181
Chloroquine, 215
Cholestyramine, 290P
Cimetidine, 618P
Cisplatin, 625P
Clinical Pharmacology studies, 347
Clinical interpretation, 95
Clinical panels, 278P
Clinical pharmacy, 278P, 415
Clinical trials, 147
Clozapine, 282P, 453
Clozapine-N-oxide, 453
Cognitive function,
Complex formation, 377
Compliance, 620P
Compliance with subsidy restrictions, 409
Computer simulations, 321
Concentration-effect modelling, 383
Conjunctival instillation, 272
Constipation, 255
Continuous rate infusion, 163
Covariate analysis, 117
Creatinine clearance, 447
Cyclophosphamide, 619P
Cyclosporin A, 624P, 626P
Cysteine deficiency, 285P
Cytochrome P450, 55, 176, 221, 290P, 535
Cytochrome P450–2D6 87

Delayed release mesalazine, 173
Deprenyl, 284P
Diabetes mellitus, type II, 630P
Diazepam, 628P
Diclofenac, 304P
Didanosine, 283P
Dihydroartemesinin, 293P
Dihydroergotamine, 623P
Dihydropyrimidine, 151
Dihydropyrimidine dehydrogenase, 1, 151
Discharge information, 300P
Diuretics, 403
Dose-response curve, 589
Drug cocktail, 215
Drug developer, 352
Drug development, 351
Drug disposition, 355
Drug input rate, 479
Drug interaction, 1, 101, 111, 377, 563
Drug interactions, 627P
Drug metabolism, 151
Drug regulator, 352
Drug safety monitoring, 195
Drug utilization, 409
Drug-induced hepatotoxicity, 357
Drugs and the liver, 351
Duration of action, 127

Effect compartment 237, 383
Elderly, 363, 531, 625P
Enalapril 583
Enantiomers, 79, 290P, 441, 627P
Endogenous production, 11
Endothelial function, 279P, 517
Endothelium, 489
Epilepsy, 547, 626P
Epoetin B, 11
Eprosartan, 267
Erythropoietin, 11
Ethinyloestradiol, 111
Ethoxyresorufin 55
Etoposide, 627P
Exercise blood pressure, 288P

Fentanyl, 37
Fibrinogen, 473
5-fluorouracil, 1
Fluvastatin, 49
Food, 83, 433, 630
Forearm vasculaature, 281P
Freundlich isotherm, 299P
Frusemide, 479, 571, 624P, 625P
Furafylline, 55

GPIIb-IIIa, 139
GR205171, 297P
GR233548, 281P
Gastrointestinal haemorrhage, 88
Gender, 83, 267, 505, 612
Gene-dose effect, 499
General practice, 505
General practitioners, 279, 300P
Genetic aspects, 361
Genotype, 499
Gentamicin, 229
Glucuronidation, 111
Glycoprotein IIb/IIIa receptor antagonist, 281P
Glycosalicylate, 29
GR205171, 298P
Grapefruit juice, 101, 629P

HCV-RNA, 563
HIV infected patients, 285P, 620P
HIV positive patients, 621P
HIV protease inhibitors, 291P
HIV-1 infection, 518
HIV-protease inhibitors, 295P

© 1998 Blackwell Science Ltd

Haemodialysis, 21
Haemodynamics, 383
Haemoglobin, 461
Haemorheology 473
Halothane hepatitis, 303P
Hand vein, 280P
Health professionals, 278P
Healthy volunteers, 383, 541
Heart failure, 279P, 360, 377, 421, 624P
Helicobacter pylori, 302P
Hepatitis, 251
Hepatitis C, 176, 563
Hepatotoxicity, 304P, 355
5-HT1A/1D receptor agonists, 577
Human, 83, 425
Human arteries, 577
Hydrocortisone, 589
Hydroxyurea, 283P
Hyperglycaemia, 289P
Hyperlipidaemia, 473, 518
Hypertension, 63, 363, 377
Hypertension treatment, 467

Ibopamine, 71
Ibuprofen, 304P
Idiosyncratic toxicity, 285P
Ileostomy, 207
Illicit drug use, 237P, 301P P
Impedance, 489
Impedance cardiography, 489
Indinavir, 620P
Induction, 111
Infants, 395
Inflammatory bowel disease, 207
Inhibition, 215
Insulin sensitivity, 467
Interaction, 49, 83, 271
Interactions, 441
Interferon alfa-2b, 563
Interleukin-2, 5
Internal mammary artery, 571
Intestinal drug metabolism, 101
Intranasal formulation, 623P
Intravenous, 203
Inulin clearance, 605
Irbesartan, 612
Iron, 377
Isomerisation, 293P
Itraconazole, 49, 271

Junior hospital doctors, 278

Kidney volume, 447
Kinetic analysis, 605

L-758,298, 282P
Lacidipine, 127
Lactulose, 173
Lamivudine, 21, 283P, 547, 626P
Langmuir isotherm, 299P
Laxatives, 255
Lean body mass, 447
Left ventricular ejection fraction, 624P
Levobupivacaine, 245
Lifestyle variables, 301P
Lipoproteins, 473
Lisinopril, 467
Liver, 251
Liver clearance, 176
Liver damage, 303P
Liver disease, 351
Liver impairment, 354, 355
Liver volume, 447
Loop diuretics P 628
Losartan, 169, 467, 583
Lovastatin, 49
Low dose MEGX test, 535
Low-density lipoprotein, 288P
Lung delivery, 45
Lung fibrosis, 618P

Malaria, 553
Malaria, cerebral, 629P
Medical students, 301P
Meloxicam, 133
Memantine, 541
Metabolic ratio, 499
Metabolic risk factors, 288P
Metabolism, 215, 221
Methotrexate, 369
Methylprednisolone, 618P
Methylsalicylate, 29
Metoprolol, 622P
Metronidazole clearance, 176
Microdialysis, 425
Midazolam, 203, 395
Migraine, 290P
Mitomycin C, 300P
Mixed hyperlipoproteinaemia, 473
Moclobemide, 628P
Monoethylglycinexylidide test, 535
Mortality, 71
Motion sickness, 282P
Mucosal blood flow, 133
Myocardial infarction, 335
Mitomycin, 299P

N-desmethylclozepine, 453
NONMEM 11, 117, 461
Nausea, 297P
Neopterin, 563
Neurokinin-1 receptor antagonist, 282P, 297P
Neutrophil, 139
Neutrophil apoptosis, 292P
Nitrate, 517
Nitric oxide, 139, 263, 489, 622P
Non-CFC metered dose inhaler, 45
Non-compartmental analysis, 489
Non-steroidal anti-inflammatory drugs, 133
Noradrenaline, 589
Norfloxacin, 272
Nucleoside analogues, 283P
Nursing home patients, 255

OPA/n-acetyl-L-cysteine, 627P
Ocular, 181
Olanzapine, 301P
2′5′-oligoadenylate synthetase, 563
Omeprazole, 173
Ondansetron, 117
Oral contraceptive, 111
Oxidative stress, 279P

P-glycoprotein, 295P
P-selectin, 139
PK-PD modelling, 383
Paclitaxel, 624P, 626P
Paracetamol, 237, 425, 513
Parkinsonism, 302P
Percutaneous, 29
Perindopril, 63
Peripheral resistance, 489
Permeable superoxide dismutase, 288P
Peroxide antimalarials, 521
Pharmacodynamics, 101, 237, 321, 441, 461, 479, 563, 599, 622P, 628P
Pharmacoepidemiology, 195
Pharmacogenetics, 151
Pharmacokinetics, 5, 21, 37, 49, 83, 101, 111, 163, 203, 221, 237, 267, 271, 290P, 297P, 298P, 363, 433, 441, 541, 563, 612, 618P, 622P, 623P, 627P, 628P
Pharmacovigilance, 195
pH-dependent drug delivery, 173
Piroxicam, 133
Plasma protein binding, 291P, 453
Platelet, 139
Polymorphism, 151
Population analysis, 461
Population models, 321
Population pharmacokinetics, 11, 117, 229, 369, 553
Post prandial blood pressure, 625P
Postmarketing surveillance, 63, 505
Pre-eclampsia, 622P
Premature infants, 163
Presciption sequence analysis, 255
Prescribing, 531
Prescription event monitoring, 195, 505
Prescription patterns 403
Pressor response, 297P
Priapism, 343
Primary care, 415
Prior therapy, 409
Proguanil, 499
Propafenone, 441
Propranolol, 281P
Protease inhibitors, 111, 518
Protein, 300P
Proton pump inhibitors, 409
Publication bias, 147
Pulmonary administration, 37
Pulmonary circulation, 263

Quality control, 147
Quinapril, 599

RIG-200, 280P
Rac-bupivacaine 245
Racial differences 441
Rectal administration, 622P
Red cell aggregation, 473
Relative activity factor, 55
Renal clearance, 453
Renal elimination, 541
Renal function, 21
Research Ethics Committees, 347
Retrodialysis, 88
Rheumatoid arthritis, 369
Ribavirin, 563
Rifampicin, 535
Risk factors, 71
Ritonavir, 111

S(-) enantiomer, 245
SPI-77, 625P
Safety, 298P
Safety assessment, 521
Salbutamol, 45

Saliva, 425
Saphenous vein, 571
Saquinavir, 291P, 295P
Schizophrenia, 301P
Scopolamine, 282P
Sedation, 395
Selective inhibition, 215
Selegiline, 284P, 297P
Septic shock, 589
Sigmoid model, 383
Skin blister, 425
Sleep deprivation, 285P
Small and large volume plastic spacers, 45
Sodium nitroprusside, 280P
Soluble interleukin-2 receptor, 5
Sorivudine, 1
(+)-sotalol, 79
(±)-sotalol, 79
Sphygmocor system,286P
Subcutaneous, 5
Subcutaneous administration, 11
Sulphamethazole, 285P
Sulphation, 513
Sulphonamides, 305P
Sulphones, 305P
Sustained-release, 207
Systemic circulation, 263

Tacrine, 221
Tacrolimus, 271
Tamoxifen, 296P
Temocapril, 363
Temocaprilat, 363
Terfenadine, 251
Therapeutic drug monitoring, 93, 95, 185, 307, 547
Therapeutic management, 95
Therapeutic response, 553
ThioTEPA, 619P
Thromboembolism, 343
Thyrotoxicosis, 421
Tolerability, 298P, 628P 298
Tolerance, 479
Topotecan, 630P
Toxicity, 305P 305
Transplant patients, 271
Tricyclic antidepressants, 631P
Triethanolamine, 29
Tubular secretion, 453
Tucaresol, 83
Tyramine, 297P

Ulcerative colitis, 173, 513
Unstable angina, 335
Urinary flow, 541
Urine pH, 541

Vancomycin, 163
Vascular responsiveness, 127
Vasoconstriction, 577
Vasoconstrictor agents, 127
Ventilatory function, 79
Vigabatrin, 626P, 627P 626
Vitamin C, 279P, 288P 279
Volunteers, 245

Warfarin, 157, 290P
Warfarin resistance, 343

Zabicipril, 383
Zidovudine, 283P, 294P
Zolmitriptan, 290P, 433
Zydis, 284P